SPCC1259.16 Antibody

What is SPCC1259.16 antibody and what is its target specificity?

SPCC1259.16 antibody (catalog BT1675054) appears to target a protein related to MUC16, a transmembrane mucin with cleaved extracellular domain (CA125) that serves as an important biomarker in ovarian cancer research. The antibody is formulated in liquid form containing 50% glycerol, 0.01M PBS at pH 7.4, with 0.03% Proclin 300 as preservative.

Based on available research, MUC16 has a complex structure comprising approximately 22,000 amino acids with heavily glycosylated tandem repeats and distinctive SEA (Sperm protein, Enterokinase, Agrin) domains. SPCC1259.16 antibody likely targets non-glycosylated epitopes, which is consistent with modern antibody development strategies focusing on stable recognition regions.

How does SPCC1259.16 antibody differ from other MUC16-targeting antibodies?

SPCC1259.16 antibody represents one of several approaches to targeting MUC16. Current research distinguishes between different antibody types based on their target epitopes and applications:

SPCC1259.16 antibody likely belongs to the category targeting non-glycosylated regions, which offers advantages in consistent epitope recognition across different tissue sources and disease states.

What experimental validation confirms SPCC1259.16 antibody specificity?

Comprehensive validation should include:

• Western blot analysis showing a band consistent with the predicted molecular weight of the target

• Peptide competition assays demonstrating signal reduction when pre-incubated with immunizing peptide

• Knockdown/knockout controls using siRNA or CRISPR-Cas9 targeted to the putative target

• Cross-reactivity assessment across multiple species and related proteins

• Comparison with alternative antibodies targeting the same protein

Researchers should conduct these validation steps before employing SPCC1259.16 antibody in critical experiments to ensure reliability of results.

What are the optimal conditions for using SPCC1259.16 antibody in Western blotting?

For Western blot applications using SPCC1259.16 antibody, researchers should consider:

• Sample preparation: Standard lysis in RIPA buffer with protease inhibitors; both reducing and non-reducing conditions should be tested as MUC16 contains numerous disulfide bonds that may affect epitope accessibility

• Initial dilution range: 1:500-1:2000 in 5% BSA/TBST

• Incubation conditions: Overnight at 4°C with gentle rocking

• Positive controls: Lysates from MUC16-expressing cell lines (e.g., OVCAR-3, SKOV-3)

• Detection system: HRP-conjugated secondary antibody with enhanced chemiluminescence

Given the large size of MUC16 (~22,000 amino acids), gradient gels (4-15%) are recommended for optimal separation, with extended transfer times (overnight at low voltage) to ensure complete protein transfer.

Can SPCC1259.16 antibody be used for immunoprecipitation of native target protein?

While specific data for SPCC1259.16 is limited, immunoprecipitation of MUC16-related proteins typically requires:

• Gentle lysis conditions (NP-40 or Triton X-100 based buffers rather than RIPA) to preserve protein-protein interactions

• Pre-clearing of lysates with Protein A/G beads to reduce non-specific binding

• Antibody amounts between 2-5 μg per 500 μg of total protein

• Extended incubation (overnight at 4°C) to maximize antigen capture

• Stringent washing (4-5 washes) to reduce background

Researchers should optimize the protocol based on their specific experimental system, particularly considering the large size and heavily glycosylated nature of MUC16 which may affect extraction efficiency and antibody accessibility.

What troubleshooting approaches are recommended when SPCC1259.16 antibody shows poor signal-to-noise ratio?

When facing high background or weak signal with SPCC1259.16 antibody, consider:

• Antibody titration: Test broader dilution series (1:100 to 1:5000)

• Blocking optimization: Compare BSA vs. non-fat milk; consider fish gelatin for problematic samples

• Buffer modifications: Add 0.1% Tween-20 to reduce hydrophobic interactions

• Incubation temperature: Compare room temperature vs. 4°C incubation

• Secondary antibody cross-adsorption: Use highly cross-adsorbed secondary antibodies to minimize non-specific binding

• Sample quality assessment: Verify protein integrity with general protein stains

For MUC16-related targets specifically, glycosylation heterogeneity can significantly impact antibody performance across different sample types, necessitating application-specific optimization.

How can SPCC1259.16 antibody be employed in studies of MUC16 cleavage mechanisms?

MUC16 undergoes proteolytic cleavage, generating a shed extracellular domain (CA125) and a retained membrane-bound fragment. To study this process:

• Design experiments comparing antibodies targeting different domains (extracellular vs. membrane-proximal)

• Use SPCC1259.16 in combination with antibodies against the cleaved CA125 domain to study cleavage kinetics

• Apply protease inhibitors to identify enzymes responsible for processing

• Employ site-directed mutagenesis of putative cleavage sites followed by antibody detection

• Quantify shed CA125 in media while measuring retained fragments in cellular fractions

Current research highlights the challenges in understanding MUC16 cleavage dynamics, which limits therapeutic antibody efficacy . SPCC1259.16 may prove valuable in characterizing these mechanisms if it targets membrane-proximal regions.

What are the considerations for using SPCC1259.16 antibody in therapeutic development research?

When evaluating SPCC1259.16 antibody for therapeutic applications, researchers should assess:

• Binding affinity: Determine KD values using surface plasmon resonance or bio-layer interferometry

• Internalization rate: Quantify antibody uptake using fluorescently-labeled antibody and live-cell imaging

• Functional effects: Measure impact on proliferation, migration, and survival of MUC16-expressing cells

• Effector function activation: Assess ADCC and CDC potential with appropriate cellular assays

• Cross-reactivity profile: Evaluate binding to related proteins and normal tissues

Notable findings from other MUC16-targeting antibodies provide context: 4H11 demonstrates efficient internalization (721-fold uptake in 48 hours) with 6.8 nM affinity, while M16Ab shows slower internalization (t1⁄2β = 92.4 hrs), making it suitable for radioimmunotherapy approaches.

How does glycosylation heterogeneity affect SPCC1259.16 antibody performance across different experimental systems?

MUC16 glycosylation varies significantly by tissue origin, disease state, and cell culture conditions, creating challenges for antibody-based detection:

• Glycosylation can mask epitopes, leading to false negatives in heavily glycosylated samples

• Differential glycosylation between recombinant proteins and native forms may affect antibody validation results

• Enzymatic deglycosylation (PNGase F, O-glycosidase) may be necessary to expose certain epitopes

• Cell culture conditions (serum levels, growth factors) can alter glycosylation patterns

• Disease states (particularly malignancy) often feature aberrant glycosylation

If SPCC1259.16 targets non-glycosylated regions, it may offer more consistent detection across these variable conditions compared to glycosylation-dependent antibodies like OC125 and M11.

How does SPCC1259.16 antibody compare to established diagnostic antibodies for MUC16/CA125?

Clinical CA125 assays typically employ antibody pairs recognizing different epitopes. Comparing research-grade antibodies like SPCC1259.16 with clinical diagnostic antibodies:

• Diagnostic antibodies (OC125/M11) primarily target glycosylated tandem repeat domains, while research antibodies often target conserved protein domains

• Commercial diagnostic assays use antibody combinations to improve sensitivity (e.g., OC125/M11 combo assays), whereas research applications may use single antibodies

• Diagnostic antibodies undergo extensive validation for clinical use, while research antibodies focus on specific experimental applications

• The 4H11 antibody demonstrated 56% concordance with the diagnostic antibody OC125 in ovarian carcinomas but detected 12 OC125-negative cases, highlighting the importance of epitope selection

The potential unique epitope recognition of SPCC1259.16 may complement diagnostic approaches, particularly for cases where standard CA125 assays yield negative results despite disease presence.

What experimental designs can evaluate SPCC1259.16 antibody for immunotherapy applications?

To assess SPCC1259.16 potential for immunotherapeutic approaches:

• Generate chimeric antigen receptor (CAR) constructs incorporating SPCC1259.16 scFv regions

• Develop bispecific antibody formats linking SPCC1259.16 binding domains with T-cell engaging components

• Evaluate SPCC1259.16-drug conjugates for targeted delivery to MUC16-expressing tumors

• Assess combination approaches with anti-angiogenic therapies (previous MUC16-targeting bispecifics showed 70% tumor reduction when combined with anti-VEGF therapy)

• Compare SPCC1259.16 CAR-T cell efficacy with established approaches like 4H11-28z-MUC-CD, which demonstrated effectiveness against MUC16-Cter+ ovarian cancer cells

Successful immunotherapeutic application will depend on SPCC1259.16 specificity, binding affinity, and epitope accessibility in the tumor microenvironment.

What emerging techniques could enhance SPCC1259.16 antibody applications in MUC16 research?

Cutting-edge approaches that could expand SPCC1259.16 utility include:

• Super-resolution microscopy to visualize MUC16 distribution and dynamics at nanoscale resolution

• Single-cell proteomics to correlate MUC16 expression with cellular phenotypes

• Antibody engineering to generate site-specific conjugates with improved therapeutic index

• Proximity labeling approaches (BioID, APEX) using SPCC1259.16 to identify MUC16 interaction partners

• CRISPR screens to identify synthetic lethal interactions in MUC16-dependent cells that could be targeted in combination with SPCC1259.16-based therapeutics

These advanced techniques could address current limitations in understanding MUC16 biology and accelerate therapeutic development targeting this important cancer biomarker.